Tier-two pharma picks show solid fundamentals, but Eli Lilly (LLY) stock stands out for its growth potential. Read here for ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Viking Therapeutics (NASDAQ:VKTX) fell ~43% as analysts reacted to mid-stage trial data for its oral GLP-1/GIP dual receptor ...

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

To provide a brief background, the TRAILBLAZER-ALZ 2 LTE study was a Phase 3, double-blind extension of the original ...

We recently published 10 Stocks On Jim Cramer’s Radar Including Big Tech Firms. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) ...

The deal allows Eli Lilly and Company (NYSE:LLY) to have exclusive rights to develop and commercialize drug candidates ...

Eli Lilly and Company (NYSE:LLY) is included in our list of the 11 Best Rebound Stocks to Buy According to Hedge Funds. On August 8, 2025, JPMorgan maintained its ‘Overweight’ rating on Eli Lilly and ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.